Artivion, Inc. AORT | NYSE
|2026-09-03
Company Overview:
10 Year AORT Performance Metrics:
AORT Dividend Charts
Build Custom Charts
AORT Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
AORT Dividends Info:
AORT Dividend History: Dates, Payments & Yield list
Below is a schedule of all AORT dividend payments, ex-dates, share price on the day of the payment as well as the annualized yield & forward yield
| Ex-Date | Payment Date | Amount | Yield | Forward Yield | Price on Ex-Date |
|---|---|---|---|---|---|
| 12/09/2015 | 12/18/2015 | $0.030 | 1.15% | 1.17% | $10.26 |
| 09/09/2015 | 09/18/2015 | $0.030 | 1.24% | 1.26% | $9.51 |
| 06/10/2015 | 06/19/2015 | $0.030 | 1.07% | 1.07% | $11.20 |
| 03/11/2015 | 03/20/2015 | $0.030 | 1.16% | 1.19% | $10.12 |
| 12/10/2014 | 12/19/2014 | $0.030 | 1.15% | 1.17% | $10.28 |
| 09/10/2014 | 09/19/2014 | $0.030 | 1.2% | 1.18% | $10.21 |
| 06/11/2014 | 06/20/2014 | $0.030 | 1.33% | 1.32% | $9.07 |
| 03/12/2014 | 03/21/2014 | $0.028 | 1.16% | 1.14% | $9.65 |
| 12/11/2013 | 12/20/2013 | $0.028 | 1.09% | 1.03% | $10.66 |
| 09/11/2013 | 09/20/2013 | $0.028 | 1.72% | 1.58% | $6.95 |
| 06/12/2013 | 06/21/2013 | $0.028 | 1.79% | 1.77% | $6.21 |
| 03/12/2013 | 03/21/2013 | $0.025 | 1.63% | 1.7% | $5.89 |
| 12/12/2012 | 12/21/2012 | $0.025 | 1.67% | 1.59% | $6.27 |
| 09/12/2012 | 09/21/2012 | $0.025 | 1.79% | 1.69% | $5.92 |
Projected Future Returns & Dividends for AORT
Based on past 10-year performance, here are AORT growth metrics:
Share price CAGR of +0.21%
Dividend CAGR of +5.79%
Using AORT CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| AORT (DRIP) | AORT - No DRIP | |
|---|---|---|
| Current Price | $19.10 | $19.10 |
| Start Shares | 523.56 | 523.56 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 567.77 | 523.56 |
| Dividends Payment | $0.05 | $0.05 |
| Annual Dividends | $120 | $110 |
| Yield on cost | 1.20% | 1.10% |
| Share Price | $19.51 | $19.51 |
| Total Dividends | $853 | $820 |
| Final Value | $11,076 | $11,034 |
NOTE: Above numbers are our estimate based on AORT's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Artivion, Inc. (AORT) had its IPO on 1993-02-12, and is traded on NYSE stock exchange.
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
AORT website: https://artivion.com
DCF Model — AORT
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
